Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Current Bladder Dysfunction Reports
Published in: Current Bladder Dysfunction Reports 4/2016

01-12-2016 | Post-Prostatectomy and Acquired Voiding Dysfunction (V Tse, Section Editor)

Interstitial Cystitis/Bladder Pain Syndrome: a Review and an Update

Authors: Zhiwei Fang, Kexin Xu

Published in: Current Bladder Dysfunction Reports | Issue 4/2016

Login to get access

Abstract

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic condition characterized by pelvic pain and lower urinary tract symptoms. The evolution of nomenclature of IC/BPS has experienced a long history. The disease etiology is not yet fully understood; potential pathophysiologic causes proposed include defect of layer of glycosaminoglycan (GAG) on the apical surface of bladder floor; autoimmune, inflammatory, and neurogenic mechanisms; infection; and so on. There are a lot of strategies to cure IC/BPS, mainly including behavioral therapy, oral medicines, intravesical treatments, and intradetrusor botulinum toxin A (BTXA) injection. But none of them is curative. Most treatments are aimed at controlling symptom and improving the quality of life of patients. In this article, we will talk about the new progress of definition, etiology, and treatment on IC/BPS.
Literature
1.
The standardization of terminology of lower urinary tract function: report from the standardization sub-committee of the International Continence Society.
2.
Oravisto KJ. Epidemiology of interstitial cystitis. Annales chirurgiae et gynaecologiae Fenniae. 1974.
3.
CK Payne GFJ, M Wise JQC. Interstitial cystitis and painful bladder syndrome. 2007.
4.
JQ Clemens RTM, MCOK ROSETTI SYG. Prevalence and incidence of interstitial cystitis in a managed care population. 2005.
5.
SH Berry LMB, C Pham KL, Nyberg L. Development, validation and testing of an epidemiological case definition of interstitial cystitis/painful bladder syndrome. 2010.
6.
AM Suskind SHB, BA Ewing MNE. The prevalence and overlap of interstitial cystitis/bladder pain syndrome and chronic prostatitis/chronic pelvic pain syndrome in men: results of the RAND Interstitial Cystitis Epidemiology male study. 2013.
7.
Berry SH, Elliott MN, Suttorp M, et al. Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States. J Urol. 2011;186(2):540–4.CrossRefPubMedPubMedCentral
8.
Krieger JN, Riley DE, Cheah PY, Liong ML, Yuen KH. Epidemiology of prostatitis: new evidence for a world-wide problem. World J Urol. 2003;21(2):70–4.CrossRefPubMed
9.
Clemens JQ, Meenan RT, O’Keeffe-Rosetti MC, Gao SY, Brown SO, Calhoun EA. Prevalence of prostatitis-like symptoms in a managed care population. J Urol. 2006;176(2):593–6. discussion 596.CrossRefPubMed
10.
Mehik A, Hellstrom P, Lukkarinen O, Sarpola A, Jarvelin M. Epidemiology of prostatitis in Finnish men: a population-based cross-sectional study. BJU Int. 2000;86(4):443–8.CrossRefPubMed
11.
Skene A. Diseases of the bladder and urethra in women. Am J Med Sci. 1879.
12.
Hünner GL. A rare type of bladder ulcer in women. Tr. South. Surg. Gynecol. Assoc.. 1914.
13.
DJ Clauw MS, D Radulovic AS. The relationship between fibromyalgia and interstitial cystitis. 1997.
14.
Hanno PM, Landis JR, Matthews-Cook Y, Kusek J, Nyberg Jr L. The diagnosis of interstitial cystitis revisited: lessons learned from the National Institutes of Health Interstitial Cystitis Database study. J Urol. 1999;161(2):553–7.CrossRefPubMed
15.
•Gillenwater JY, Wein AJ. Summary of the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases Workshop on Interstitial Cystitis, National Institutes of Health, Bethesda, Maryland, August 28–29, 1987. J Urol. 1988;140(1):203–6. Covers the classic criteria of interstitial cystitis/bladder pain syndrome (IC/BPS).PubMed
16.
Hanno P, Dmochowski R. Status of international consensus on interstitial cystitis/bladder pain syndrome/painful bladder syndrome: 2008 snapshot. Neurourol Urodyn. 2009;28(4):274–86.CrossRefPubMed
17.
van de Merwe JP, Nordling J, Bouchelouche P, et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol. 2008;53(1):60–7.CrossRefPubMed
18.
Ito T, Ueda T, Honma Y, Takei M. Recent trends in patient characteristics and therapeutic choices for interstitial cystitis: analysis of 282 Japanese patients. Int J Urol. 2007;14(12):1068–70.CrossRefPubMed
19.
•Homma Y. Hypersensitive bladder: a solution to confused terminology and ignorance concerning interstitial cystitis. Int J Urol. 2014;21 Suppl 1:43–7. Article covers new term drawing a distinction between interstitial cystitis and IC-like patients.CrossRefPubMed
20.
Hicks RM, Ketterer B, Warren RC. The ultrastructure and chemistry of the luminal plasma membrane of the mammalian urinary bladder: a structure with low permeability to water and ions. Philos Trans R Soc Lond B Biol Sci. 1974;268(891):23–38.CrossRefPubMed
21.
Hurst RE, Meerveld BG, Wisniewski AB, et al. Increased bladder permeability in interstitial cystitis/painful bladder syndrome. Transl Androl Urol. 2015;4(5):563–71.PubMedPubMedCentral
22.
••Kreft ME, Sterle M, Veranic P, Jezernik K. Urothelial injuries and the early wound healing response: tight junctions and urothelial cytodifferentiation. Histochem Cell Biol. 2005;123(4–5):529–39. Defect of GAG layer is the most famous hypothesis of IC/BPS, and it provides theoretical basis for GAG layer replenishment treatment.CrossRefPubMed
23.
Varley CL, Garthwaite MA, Cross W, Hinley J, Trejdosiewicz LK, Southgate J. PPARgamma-regulated tight junction development during human urothelial cytodifferentiation. J Cell Physiol. 2006;208(2):407–17.CrossRefPubMedPubMedCentral
24.
Buckley MS, Washington S, Laurent C, Erickson DR, Bhavananadan VP. Characterization and immunohistochemical localization of the glycoconjugates of the rabbit bladder mucosa. Arch Biochem Biophys. 1996;330(1):163–73.CrossRefPubMed
25.
Stanford EJ, Dell JR, Parsons CL. The emerging presence of interstitial cystitis in gynecologic patients with chronic pelvic pain. Urology. 2007;69(4 Suppl):53–9.CrossRefPubMed
26.
Buffington CA, Woodworth BE. Excretion of fluorescein in the urine of women with interstitial cystitis. J Urol. 1997;158(3 Pt 1):786–9.CrossRefPubMed
27.
Janssen DA, van Wijk XM, Jansen KC, van Kuppevelt TH, Heesakkers JP, Schalken JA. The distribution and function of chondroitin sulfate and other sulfated glycosaminoglycans in the human bladder and their contribution to the protective bladder barrier. J Urol. 2013;189(1):336–42.CrossRefPubMed
28.
Erickson DR, Herb N, Ordille S, Harmon N. A new direct test of bladder permeability. J Urol. 2000;164:419–22.CrossRefPubMed
29.
Towner RA, Wisniewski AB, Wu DH, et al. A feasibility study to determine whether clinical contrast enhanced magnetic resonance imaging can detect increased bladder permeability in patients with interstitial cystitis. J Urol. 2015.
30.
Johansson SL, Fall M. Clinical features and spectrum of light microscopic changes in interstitial cystitis. J Urol. 1990.
31.
Said JW, Van de Velve R, Gillespie L. Immunopathology of interstitial cystitis. 1989.
32.
Keay S, Zhang CO, Trifillis AL, Hebel JR, Jacobs SC. Urine autoantibodies in interstitial cystitis. 1997.
33.
Altuntas CZ, Daneshgari F, Sakalar C, Goksoy E. Autoimmunity to uroplakin II causes cystitis in mice: a novel model of interstitial cystitis. Eur Urol. 2012;61:193–200.CrossRefPubMed
34.
Izgi K, Altuntas CZ, Bicer F, et al. Uroplakin peptide-specific autoimmunity initiates interstitial cystitis/painful bladder syndrome in mice. PLoS One. 2013;8(8), e72067.CrossRefPubMedPubMedCentral
35.
Carter HB. American Urological Association (AUA) guideline on prostate cancer detection: process and rationale. BJU Int. 2013;112(5):543–7.CrossRefPubMed
36.
Peters KM, Killinger KA, Ibrahim IA. Childhood symptoms and events in women with interstitial cystitis/painful bladder syndrome. Urology. 2009;73(2):258–62.CrossRefPubMed
37.
Warren JW, Brown V, Jacobs S, Horne L, Langenberg P, Greenberg P. Urinary tract infection and inflammation at onset of interstitial cystitis/painful bladder syndrome. Urology. 2008;71(6):1085–90.CrossRefPubMed
38.
Zhang QH, Shen XC, Zhou ZS, Chen ZW, Lu GS, Song B. Decreased nanobacteria levels and symptoms of nanobacteria-associated interstitial cystitis/painful bladder syndrome after tetracycline treatment. Int Urogynecol J. 2010;21(1):103–9.CrossRefPubMed
39.
40.
Verit A, Guner ND. Helicobacter pylori and urinary system stones: endoluminal damage as sub-hypothesis to support the current stone theory. Med Hypotheses. 2014;83(6):677–80.CrossRefPubMed
41.
Staack A, Distelberg B, Schlaifer A, Sabate J. Prospective study on the effects of regular and decaffeinated coffee on urinary symptoms in young and healthy volunteers. Neurourol Urodyn. 2015.
42.
AN Pierce JAC. Chapter seventeen—stress and chronic pelvic pain. Progress in molecular biology and translational science. 2015.
43.
Lee UJ, Ackerman AL, Wu A, et al. Chronic psychological stress in high-anxiety rats induces sustained bladder hyperalgesia. Physiol Behav. 2015;139:541–8.CrossRefPubMed
44.
Foster Jr HE, Hanno PM, Nickel JC, et al. Effect of amitriptyline on symptoms in treatment naive patients with interstitial cystitis/painful bladder syndrome. J Urol. 2010;183(5):1853–8.CrossRefPubMedPubMedCentral
45.
Dinis S, de Oliveira JT, Pinto R, Cruz F, Buffington CT, Dinis P. From bladder to systemic syndrome: concept and treatment evolution of interstitial cystitis. Int J Womens Health. 2015;7:735–44.CrossRefPubMedPubMedCentral
46.
Yang W, Propert KJ, Richard LJ. Estimating the efficacy of an interstitial cystitis/painful bladder syndrome medication in a randomized trial with both non-adherence and loss to follow-up. Stat Med. 2014;33(20):3547–55.CrossRefPubMed
47.
Sun Y, Fang Z, Ding Q, Zheng J. Effect of amitriptyline in treatment interstitial cystitis or bladder pain syndrome according to two criteria: does ESSIC criteria change the response rate. Neurourol Urodyn. 2014;33(3):341–4.CrossRefPubMed
48.
Holm-Bentzen M, Jacobsen F, Nerstrom B, et al. A prospective double-blind clinically controlled multicenter trial of sodium pentosanpolysulfate in the treatment of interstitial cystitis and related painful bladder disease. J Urol. 1987;138(3):503–7.PubMed
49.
Sant GR, Propert KJ, Hanno PM, et al. A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis. J Urol. 2003;170(3):810–5.CrossRefPubMed
50.
Mulholland SG, Hanno P, Parsons CL, Sant GR, Staskin DR. Pentosan polysulfate sodium for therapy of interstitial cystitis. A double-blind placebo-controlled clinical study. Urology. 1990;35(6):552–8.CrossRefPubMed
51.
Parsons CL, Benson G, Childs SJ, Hanno P, Sant GR, Webster G. A quantitatively controlled method to study prospectively interstitial cystitis and demonstrate the efficacy of pentosanpolysulfate. J Urol. 1993;150(3):845–8.PubMed
52.
Nickel JC, Herschorn S, Whitmore KE, et al. Pentosan polysulfate sodium for treatment of interstitial cystitis/bladder pain syndrome: insights from a randomized, double-blind, placebo controlled study. J Urol. 2015;193(3):857–62.CrossRefPubMed
53.
Giannantoni A, Bini V, Dmochowski R, et al. Contemporary management of the painful bladder: a systematic review. Eur Urol. 2012;61(1):29–53.CrossRefPubMed
54.
Perez-Marrero R, Emerson LE, Feltis JT. A controlled study of dimethyl sulfoxide in interstitial cystitis. J Urol. 1988;140(1):36–9.PubMed
55.
Yamada Y, Nomiya A, Niimi A, et al. A survey on clinical practice of interstitial cystitis in Japan. Transl Androl Urol. 2015;4(5):486–90.PubMedPubMedCentral
56.
Neuhaus J, Schwalenberg T. Intravesical treatments of bladder pain syndrome/interstitial cystitis. Nat Rev Urol. 2012;9(12):707–20.CrossRefPubMed
57.
Tomoe H. In what type of interstitial cystitis/bladder pain syndrome is DMSO intravesical instillation therapy effective. Transl Androl Urol. 2015;4(6):600–4.PubMedPubMedCentral
58.
Peeker R, Haghsheno MA, Holmang S, Fall M. Intravesical bacillus Calmette-Guerin and dimethyl sulfoxide for treatment of classic and nonulcer interstitial cystitis: a prospective, randomized double-blind study. J Urol. 2000;164(6):1912–5. discussion 1915–6.CrossRefPubMed
59.
Tomoe H. Editorial Comment from Dr Tomoe to botulinum toxin type A injection for refractory interstitial cystitis: a randomized comparative study and predictors of treatment response. Int J Urol. 2015;22(9):841–2.CrossRefPubMed
60.
Stav K, Beberashvili I, Lindner A, Leibovici D. Predictors of response to intravesical dimethyl-sulfoxide cocktail in patients with interstitial cystitis. Urology. 2012;80(1):61–5.CrossRefPubMed
61.
Hung MJ, Chen YT, Shen PS, Hsu ST, Chen GD, Ho ES. Risk factors that affect the treatment of interstitial cystitis using intravesical therapy with a dimethyl sulfoxide cocktail. Int Urogynecol J. 2012;23(11):1533–9.CrossRefPubMed
62.
Gafni-Kane A, Botros SM, Du H, Sand RI, Sand PK. Measuring the success of combined intravesical dimethyl sulfoxide and triamcinolone for treatment of bladder pain syndrome/interstitial cystitis. Int Urogynecol J. 2013;24(2):303–11.CrossRefPubMed
63.
Cervigni M. Interstitial cystitis/bladder pain syndrome and glycosaminoglycans replacement therapy. Transl Androl Urol. 2015;4(6):638–42.PubMedPubMedCentral
64.
Morales A, Emerson L, Nickel JC. Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis. Urology. 1997;49(5A Suppl):111–3.CrossRefPubMed
65.
Rooney P, Srivastava A, Watson L, Quinlan LR, Pandit A. Hyaluronic acid decreases IL-6 and IL-8 secretion and permeability in an inflammatory model of interstitial cystitis. Acta Biomater. 2015;19:66–75.CrossRefPubMed
66.
Engelhardt PF, Morakis N, Daha LK, Esterbauer B, Riedl CR. Long-term results of intravesical hyaluronan therapy in bladder pain syndrome/interstitial cystitis. Int Urogynecol J. 2011;22(4):401–5.CrossRefPubMed
67.
Parsons CL, Koziol JA, Proctor JG, Zupkas P, Argade S. Heparin and alkalinized lidocaine versus alkalinized lidocaine for treatment of interstitial cystitis symptoms. Can J Urol. 2015;22(2):7739–44.PubMed
68.
Negrete HO, Lavelle JP, Berg J, Lewis SA, Zeidel ML. Permeability properties of the intact mammalian bladder epithelium. Am J Physiol. 1996;271(4 Pt 2):F886–94.PubMed
69.
Henry RA, Morales A, Cahill CM. Beyond a simple anesthetic effect: lidocaine in the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. Urology. 2015;85(5):1025–33.CrossRefPubMed
70.
Nomiya A, Naruse T, Niimi A, et al. On- and post-treatment symptom relief by repeated instillations of heparin and alkalized lidocaine in interstitial cystitis. Int J Urol. 2013;20(11):1118–22.CrossRefPubMed
71.
Welk BK, Teichman JM. Dyspareunia response in patients with interstitial cystitis treated with intravesical lidocaine, bicarbonate, and heparin. Urology. 2008;71(1):67–70.CrossRefPubMed
72.
Parsons CL, Zupkas P, Proctor J, et al. Alkalinized lidocaine and heparin provide immediate relief of pain and urgency in patients with interstitial cystitis. J Sex Med. 2012;9(1):207–12.CrossRefPubMed
73.
Jhang JF, Jiang YH, Kuo HC. Potential therapeutic effect of intravesical botulinum toxin type A on bladder pain syndrome/interstitial cystitis. Int J Urol. 2014;21 Suppl 1:49–55.CrossRefPubMed
74.
Smith CP, Boone TB, de Groat WC, Chancellor MB, Somogyi GT. Effect of stimulation intensity and botulinum toxin isoform on rat bladder strip contractions. Brain Res Bull. 2003;61(2):165–71.CrossRefPubMed
75.
Lucioni A, Bales GT, Lotan TL, McGehee DS, Cook SP, Rapp DE. Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. BJU Int. 2008;101(3):366–70.CrossRefPubMed
76.
Kuo HC, Jiang YH, Tsai YC, Kuo YC. Intravesical botulinum toxin-A injections reduce bladder pain of interstitial cystitis/bladder pain syndrome refractory to conventional treatment—a prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial. Neurourol Urodyn. 2015.
77.
Pinto R, Lopes T, Silva J, Silva C, DInis P. Clinical response to intra-trigonal onabotulinum toxin A injections is not related to the presence of ulcers in bladder pain syndrome/interstitial cystitis patient. 2013 AUA abstract. 2013.
78.
HC Kuo MBC. Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. BJU Int. 2009 .
79.
Peng CH, Jhang JF, Shie JH, Kuo HC. Down regulation of vascular endothelial growth factor is associated with decreased inflammation after intravesical OnabotulinumtoxinA injections combined with hydrodistention for patients with interstitial cystitis—clinical results and immunohistochemistry analysis. Urology. 2013. 82(6): 1452.e1-6.
80.
Lee CL, Kuo HC. Long-term efficacy and safety of repeated intravescial onabotulinumtoxinA injections plus hydrodistention in the treatment of interstitial cystitis/bladder pain syndrome. Toxins (Basel). 2015;7(10):4283–93.CrossRef
81.
Kuo HC. Repeated onabotulinumtoxin-a injections provide better results than single injection in treatment of painful bladder syndrome. Pain Physician. 2013;16(1):E15–23.PubMed
82.
Smith CP, Radziszewski P, Borkowski A, Somogyi GT, Boone TB, Chancellor MB. Botulinum toxin a has antinociceptive effects in treating interstitial cystitis. Urology. 2004;64(5):871–5. discussion 875.CrossRefPubMed
83.
Hanno PM, Sant GR. Clinical highlights of the National Institute of Diabetes and Digestive and Kidney Diseases/Interstitial Cystitis Association scientific conference on interstitial cystitis. Urology. 2001;57(6 Suppl 1):2–6.CrossRefPubMed
84.
Adamowicz J, Pokrywczynska M, Drewa T. Conditioned medium derived from mesenchymal stem cells culture as a intravesical therapy for cystitis interstitials. Med Hypotheses. 2014;82(6):670–3.CrossRefPubMed
85.
Song M, Lim J, Yu HY, et al. Mesenchymal stem cell therapy alleviates interstitial cystitis by activating Wnt signaling pathway. Stem Cells Dev. 2015;24(14):1648–57.CrossRefPubMedPubMedCentral
86.
Colaco MA, Evans RJ. Current recommendations for bladder instillation therapy in the treatment of interstitial cystitis/bladder pain syndrome. Curr Urol Rep. 2013;14(5):442–7.CrossRefPubMed
87.
Zacche MM, Srikrishna S, Cardozo L. Novel targeted bladder drug-delivery systems: a review. Res Rep Urol. 2015;7:169–78.PubMedPubMedCentral
88.
Rajaganapathy BR, Chancellor MB, Nirmal J, Dang L, Tyagi P. Bladder uptake of liposomes after intravesical administration occurs by endocytosis. PLoS One. 2015;10(3), e0122766.CrossRefPubMedPubMedCentral
89.
Lander EB, See JR. Intravesical instillation of pentosan polysulfate encapsulated in a liposome nanocarrier for interstitial cystitis. Am J Clin Exp Urol. 2014;2(2):145–8.PubMedPubMedCentral
90.
Gong C, Qi T, Wei X, et al. Thermosensitive polymeric hydrogels as drug delivery systems. Curr Med Chem. 2013;20(1):79–94.CrossRefPubMed
91.
Nickel JC, Jain P, Shore N, et al. Continuous intravesical lidocaine treatment for interstitial cystitis/bladder pain syndrome: safety and efficacy of a new drug delivery device. Sci Transl Med. 2012;4(143):143ra100.CrossRefPubMed
Metadata
Title
Interstitial Cystitis/Bladder Pain Syndrome: a Review and an Update
Authors
Zhiwei Fang
Kexin Xu
Publication date
01-12-2016
Publisher
Springer US
Published in
Current Bladder Dysfunction Reports / Issue 4/2016
Print ISSN: 1931-7212
Electronic ISSN: 1931-7220
DOI
https://doi.org/10.1007/s11884-016-0387-y

Other articles of this Issue 4/2016

Current Bladder Dysfunction Reports 4/2016 Go to the issue

Neurogenic Bladder (C Powell, Section Editor)

Urethral Stricture in the Spinal Cord Injured Patient—What Are the Unique Considerations?

Reconstructed Bladder Function & Dysfunction (M Kaufman, Section Editor)

Minimally Invasive Approaches to Continent Urinary Diversion

Reconstructed Bladder Function & Dysfunction (M Kaufman, Section Editor)

Surgical and Metabolic Management of Urolithiasis Following Bladder Reconstruction

Reconstructed Bladder Function & Dysfunction (M Kaufman, Section Editor)

Complications and Long-Term Sequelae of Bladder Fistula Repair

Reconstructed Bladder Function & Dysfunction (M Kaufman, Section Editor)

Abdominal Imaging Following Urinary Reconstruction: Recommendations and Pitfalls

Neurogenic Bladder (C Powell, Section Editor)

Does the Technique or Pattern Matter When Injecting OnabotulinumtoxinA?